Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Treatment outcomes among childhood extensively drug-resistant tuberculosis patients in Pakistan

Muhammad Abubakar, Nafees Ahmad, Muhammad Atif, Amer Hayat Khan, Abdul Ghafoor
ERJ Open Research 2022 8: 00551-2021; DOI: 10.1183/23120541.00551-2021
Muhammad Abubakar
1Dept of Pharmacy Practice, Faculty of Pharmacy and Health Sciences, University of Balochistan, Quetta, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nafees Ahmad
1Dept of Pharmacy Practice, Faculty of Pharmacy and Health Sciences, University of Balochistan, Quetta, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: nafeesuob@gmail.com
Muhammad Atif
2Dept of Pharmacy Practice, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Muhammad Atif
Amer Hayat Khan
3Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Amer Hayat Khan
Abdul Ghafoor
4National TB Control Program, Islamabad, Pakistan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Treatment outcomes of childhood XDR-TB patients in Pakistan are better than in adult patients but still disappointing https://bit.ly/3rkQ9sw

To the Editor:

Extensively drug-resistant (XDR) tuberculosis (TB), previously defined as that caused by Mycobacterium tuberculosis concurrently resistant to isoniazid, rifampicin, any fluoroquinolone (FQ) and at least one of the three second-line injectable (SLI) drugs (amikacin, kanamycin and capreomycin), is now defined as TB caused by M. tuberculosis concurrently resistant to isoniazid, rifampicin, any FQ and at least one additional group A drug (levofloxacin, moxifloxacin, bedaquiline and linezolid) [1, 2]. It is the most difficult to treat form of TB, with an overall treatment success rate ranging from 4% to 65% [3]. Like other forms of TB, XDR-TB affects people irrespective of their age, including children (age<14 years). Although children suffering from drug-resistant (DR)-TB have a diverse spectrum of disease and adverse events, and different psychosocial, developmental and educational needs than adults, still they are treated with the same regimen as that of the adult DR-TB patients. The previously conducted, very few studies among childhood XDR-TB patients (sample size ranged from eight to 37 patients) have reported a variable rate of successful treatment outcomes (81–100%) [4, 5]. Despite Pakistan being a high DR-TB burden country, initiation of programmatic management of DR-TB (PMDT) back in 2010 [6] and >30 PMDT units all over the country [3], there was a lack of information about treatment outcomes of childhood XDR-TB patients that country. Thus, this study was conducted to evaluate the treatment outcomes among childhood XDR-TB patients in Pakistan.

Each PMDT unit in the country shares its monthly data with National TB Control Program through the Electronic Nominal Recording and Reporting System (ENRS). We used a standardised data collection form to abstract the patients’ sociodemographic, microbiological and clinical data from ENRS. The diagnosis, drug susceptibility testing (DST) and treatment of XDR-TB patients at these centres have already been discussed in our previously published paper [3]. World Health Organization (WHO) guidelines were used to categorise treatment outcomes. The outcomes “cured” and “treatment completed” were grouped as “successful outcomes”, whereas “death”, “treatment failed” and “lost to follow up” (LTFU) were grouped as “unsuccessful outcomes” [1, 3]. SPSS 20 was used for data analysis.

From October 2010 to June 2019, a total of 42 culture-confirmed childhood pulmonary XDR-TB patients were enrolled for treatment at 13 PMDT units all over Pakistan and were included in this study. The patients’ characteristics and their cross-tabulation with treatment outcomes are presented in table 1. A total of 31 (77.8%) out of 42 patients had a previous history of TB treatment. Among them, 11 had previous history of multidrug-resistant (MDR)-TB treatment. In the current cohort, the notable proportion of XDR-TB patients (n=11, 26.2%) with no history of previous TB treatment is in compliance with the recent reports stating that transmission has become an “elephant in the room” of the DR-TB epidemic and a call for better infection control measures. Screening of close contacts of an index TB case and referring the suspected DR-TB cases to PMDT sites for DST could help in reducing the transmission of XDR-TB [7–9]. The current study participants were resistant to a median of seven drugs (range 4–9). In addition to concurrent resistance to rifampicin, isoniazid, any FQ and SLI, 73.8% were resistant to pyrazinamide, 71.4% to ethambutol and 64.3% to streptomycin. Among SLIs, resistance was highest for kanamycin (73.8%), followed by capreomycin (71.4%) and amikacin (61.9%). A total of 9.5% patients were also resistant to ethionamide. Patients were treated with a median of nine drugs (range 6–12). The most commonly used drugs were pyrazinamide and cycloserine (95.2%), followed by ethionamide (85.7%), para-aminosalicylic acid (83.3%), linezolid (73.8%), moxifloxacin (59.5%), capreomycin (54.8%), co-amoxiclav (52.4%), clofazimine (47.6%), levofloxacin (38.1%), clarithromycin (35.7%), amikacin (31%), bedaquiline (11.9%), high-dose isoniazid (11.9%) and kanamycin (2.4%). A total of 29 patients (69%) achieved sputum culture conversion (SCC), defined [10] as “two successive negative cultures taken 1 month apart following a positive culture”, with a median SCC time of 2 months (interquartile range (IQR) 2–4.5 months). Time to SCC in the current cohort was comparatively shorter than that observed among XDR-TB patients in Pakistan (3 months, IQR 2–5 months) [3]. However, it was longer than the time to SCC (median 1.1 months, IQR 0.9–1.6 months) observed among childhood and adolescent MDR- and XDR-TB patients in Belarus [5]. The relatively shorter time to SCC in the later study could be due to the fact that the majority of its participants were suffering from MDR-TB rather than the most difficult to treat XDR-TB [5]. Moreover, its treatment regimen contained bedaquiline, which is reported to be associated with achieving early SCC among DR-TB patients [11, 12]. A total of 21 patients (50%) achieved successful treatment outcomes (19 cured and two treatment completed). The median duration of treatment in patients with successful outcomes was 25 months (range 22–37 months). Of the remaining 21 patients (50%) with unsuccessful outcomes, 12 (28.6%) died, four (9.5%) were declared treatment failure and five (11.9%) were LTFU. Median time to death was 6 months (range 1–19 months). Of the five patients who were LTFU, three were lost prior to achieving SCC. The current treatment success rate (50%) was above the treatment success rate of XDR-TB patients (adults and children combined) globally (39%) [13] and in Pakistan (40.6%) [3]. However, comparatively high treatment success rate among childhood XDR-TB patients has been reported by a meta-analysis (n=37, treatment success rate 81%) [4] and a study from Belarus (n=20 children and adolescents, treatment success rate 100%) [5]. Proportion of deaths (28.6%) in the current cohort was lower than that reported among XDR-TB patients (children and adults) from Pakistan (36.9%) [3] but higher than that reported by a meta-analysis of childhood XDR-TB patients (11%) [4] and a study from Belarus (children and adolescents) where no patient died, none failed the treatment and no one was LTFU [5]. The comparatively better treatment success rate in the study from Belarus could be due to the use of bedaquiline- or delamanid-containing regimens in all patients and inclusion of both children and adolescents in the study [5]. The use of a bedaquiline-containing regimen in MDR- and XDR-TB patients has been reported to be associated with early SCC and better treatment outcomes [5, 11, 12], and has been recommended by the latest WHO guidelines for the treatment of DR-TB [1]. Cross-tabulation in the current study could not yield any significant association between the patients’ variables and treatment outcomes, possibly due to limited sample size.

View this table:
  • View inline
  • View popup
TABLE 1

Distribution of treatment outcome among childhood extensively drug-resistant tuberculosis patients (N=42)

In conclusion, we report the treatment outcomes among 42 childhood XDR-TB patients who received PMDT between 2010 and 2019 in Pakistan. Although the treatment success rate was above the global and national treatment success rates (39% and 40.6% respectively) of XDR-TB patients (children and adults combined) [3, 13], it was still disappointing. Although to the best of our information, it is the largest data set of individual cohort of childhood XDR-TB patients published to date and the inclusion of nationwide cohort of childhood XDR-TB patients was the major strength of the study, limited sample size, and lack of information about adverse events, chest radiographs and their impact on treatment outcomes are the major limitations of this study. Shifting from the conventional treatment regimen containing SLIs to the recently WHO-recommended all-oral regimens [1] and individual patient data meta-analysis of treatment outcomes among large number of childhood XDR-TB patients are urgently needed.

Acknowledgments

The authors are thankful to the National TB Control Program, Islamabad for their help in data collection.

Footnotes

  • Provenance: Submitted article, peer reviewed.

  • Conflict of interest: None declared

  • Received September 13, 2021.
  • Accepted October 25, 2021.
  • Copyright ©The authors 2022
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. World Health Organization
    . WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva, World Health Organization, 2019.
  2. ↵
    1. World Health Organization
    . WHO announces updated definitions of extensively drug-resistant tuberculosis. www.who.int/news/item/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis Date last updated: 27 January 2021.
  3. ↵
    1. Abubakar M,
    2. Ahmad N,
    3. Ghafoor A, et al.
    Treatment outcomes of extensively drug-resistant tuberculosis in Pakistan: a countrywide retrospective record review. Front Pharmacol 2021; 12: 499.
    OpenUrl
  4. ↵
    1. Osman M,
    2. Harausz EP,
    3. Garcia-Prats AJ, et al.
    Treatment outcomes in global systematic review and patient meta-analysis of children with extensively drug-resistant tuberculosis. Emerg Infect Dis 2019; 25: 441–450. doi:10.3201/eid2503.180852
    OpenUrl
  5. ↵
    1. Solodovnikova V,
    2. Kumar AM,
    3. Hurevich H, et al.
    Effectiveness and safety of delamanid-or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: a nationwide study from Belarus, 2015–19. Monaldi Arch Chest Dis 2021; 91: 1646. doi:10.4081/monaldi.2021.1646
    OpenUrl
  6. ↵
    1. Ahmad N,
    2. Javaid A,
    3. Basit A, et al.
    Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance. Int J Tuberc Lung Dis 2015; 19: 1109–1114. doi:10.5588/ijtld.15.0167
    OpenUrl
  7. ↵
    1. Wahid A,
    2. Ahmad N,
    3. Ghafoor A, et al.
    Effectiveness of shorter treatment regimen in multidrug-resistant tuberculosis patients in Pakistan: a multicenter retrospective record review. Am J Trop Med Hyg 2021; 104: 1784–1791. doi:10.4269/ajtmh.20-1134
    OpenUrl
    1. Leung ECC,
    2. Leung CC,
    3. Kam KM, et al.
    Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in a metropolitan city. Eur Respir J 2013; 41: 901–908. doi:10.1183/09031936.00071212
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Shah NS,
    2. Auld SC,
    3. Brust JC, et al.
    Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med 2017; 376: 243–253. doi:10.1056/NEJMoa1604544
    OpenUrlCrossRefPubMed
  9. ↵
    1. Javaid A,
    2. Ahmad N,
    3. Afridi AK, et al.
    Validity of time to sputum culture conversion to predict cure in patients with multidrug-resistant tuberculosis: a retrospective single-center study. Am J Trop Med Hyg 2018; 98: 1629–1636. doi:10.4269/ajtmh.17-0936
    OpenUrl
  10. ↵
    1. Koirala S,
    2. Borisov S,
    3. Danila E, et al.
    Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: results from a large global cohort. Pulmonology 2021; 27: 403–412. doi:10.1016/j.pulmoe.2021.02.006
    OpenUrl
  11. ↵
    1. Borisov SE,
    2. Dheda K,
    3. Enwerem M, et al.
    Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and XDR-TB: a multicentre study. Eur Respir J 2017; 49: 1700387. doi:10.1183/13993003.00387-2017
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. World Health Organization
    . Global tuberculosis report 2018. Geneva, World Health Organization, 2018.
PreviousNext
Back to top
Vol 8 Issue 1 Table of Contents
ERJ Open Research: 8 (1)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Treatment outcomes among childhood extensively drug-resistant tuberculosis patients in Pakistan
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Treatment outcomes among childhood extensively drug-resistant tuberculosis patients in Pakistan
Muhammad Abubakar, Nafees Ahmad, Muhammad Atif, Amer Hayat Khan, Abdul Ghafoor
ERJ Open Research Jan 2022, 8 (1) 00551-2021; DOI: 10.1183/23120541.00551-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Treatment outcomes among childhood extensively drug-resistant tuberculosis patients in Pakistan
Muhammad Abubakar, Nafees Ahmad, Muhammad Atif, Amer Hayat Khan, Abdul Ghafoor
ERJ Open Research Jan 2022, 8 (1) 00551-2021; DOI: 10.1183/23120541.00551-2021
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Paediatric pulmonology
  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Expansion of ST2-expressing macrophages in a patient with bronchiolitis obliterans syndrome
  • Streptococcus pneumoniae re-emerges as a cause of community-acquired pneumonia, including frequent co-infection with SARS-CoV-2, in Germany, 2021
  • Benefit−risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis
Show more Research letter

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society